ArticlePloS one2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Michael J Thomenius et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this papercites it